GHRP-2 (Pralmorelin): What the Research Shows on Benefits, Mechanism, and Legal Status (2026)
GHRP-2, also called pralmorelin, is a synthetic hexapeptide that triggers a sharp, short-lived pulse of growth hormone by acting on the same receptor as ghrelin. Most claims about GHRP-2 benefits come from supplement marketing, not from the clinical record, so the honest version is narrower than the sales copy. GHRP-2, also called pralmorelin, is a synthetic peptide that triggers a sharp, short-lived pulse of growth hormone by acting on the same receptor as ghrelin. Its one real regulatory footprint is as a diagnostic agent in Japan, not as a treatment.
The Compound Universe Take: GHRP-2 (pralmorelin) is a growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a) and produces a rapid, potent rise in growth hormone in humans (Human evidence). It also raises appetite and can nudge cortisol and prolactin. It is approved only in Japan as a diagnostic tool for growth hormone deficiency, is banned in sport by WADA, and has no FDA approval as a therapy. Treat it as a research compound, not proven medicine.
New to this class? See the peptides studied for recovery research overview for how GHRP-2 fits alongside related compounds.
What GHRP-2 (pralmorelin) actually is
GHRP-2 is a synthetic hexapeptide first developed by Cyril Bowers and colleagues as part of the growth hormone releasing peptide family. Its sequence is unrelated to natural growth hormone releasing hormone (GHRH); instead it mimics ghrelin, the stomach-derived hunger hormone.
The distinction matters. GHRH and GHRP-2 raise growth hormone through two different receptors, which is why researchers have combined them in testing to produce a larger, synergistic response than either alone.
In Japan, pralmorelin is marketed by Kaken Pharmaceutical as GHRP Kaken 100 and is used for a single purpose: a diagnostic injection that provokes a growth hormone pulse to test for deficiency [4]. It is not sold anywhere as an approved therapeutic.
| Attribute | Detail |
|---|---|
| Class | Synthetic hexapeptide; growth hormone secretagogue (ghrelin-receptor agonist) |
| Studied for | Provoking growth hormone release; diagnosing GH deficiency; appetite |
| Evidence tier | Human (short-term hormonal and diagnostic studies) |
| Legal status (US) | Not FDA-approved; sold research-use-only; WADA-prohibited in sport |
How GHRP-2 works: the ghrelin receptor and growth hormone
GHRP-2 binds the growth hormone secretagogue receptor type 1a (GHS-R1a), the same G-protein-coupled receptor that responds to ghrelin (In-vitro / mechanistic). Activation drives calcium release inside pituitary somatotroph cells and triggers the release of stored growth hormone.
Because it acts at both the pituitary and the hypothalamus, GHRP-2 produces a strong effect. In one controlled comparison, GHRP-2 administration produced a roughly 79-fold rise in serum growth hormone in healthy control subjects (Human) [1].
That study also showed GHRP-2 could stimulate growth hormone even in patients whose GHRH receptor was mutated and non-functional, confirming that it works through a separate ghrelin-receptor pathway [1]. GHRP-2 activates the ghrelin receptor, and the ghrelin receptor drives growth hormone secretion: that two-step chain is the core of the mechanism.
What GHRP-2 benefits the research actually supports
Growth hormone release (Human evidence)
The best-documented effect is acute growth hormone secretion. Human studies consistently show a large, reproducible growth hormone pulse after GHRP-2, which is precisely why Japan approved it as a diagnostic provocation agent [1][4].
The important limit is duration. These are short-term hormonal spikes measured over minutes to hours, not evidence that repeated use safely builds muscle or reverses aging in healthy adults. No long-term human outcome trials support those popular claims.
Increased appetite and food intake (Human evidence)
In a randomized, double-blind crossover study of seven lean healthy men, GHRP-2 infusion increased calorie intake by about 36 percent versus placebo and raised reported hunger (Human) [2]. This mirrors ghrelin, which GHRP-2 imitates.
For research into cachexia or appetite loss this is relevant. For anyone seeking leanness it is a caution, not a benefit.
Cytoprotective signals (Animal / In-vitro)
A body of preclinical work has explored whether growth hormone releasing peptides protect tissue independent of growth hormone, through the ghrelin receptor and the CD36 receptor. A published review catalogs these cytoprotective effects in models of the heart, gut, and other tissues (Animal / In-vitro) [3]. These findings are mechanistic and preclinical; they do not translate to a proven human therapy.
How GHRP-2 is studied versus what is proven
The gap between the two is the whole story. GHRP-2 is a well-characterized laboratory and diagnostic tool with clear, repeatable effects on hormones. It is not an approved treatment for muscle gain, fat loss, injury recovery, or anti-aging in any major market.
Two side effects are worth naming because they undercut the marketing. GHRP-2 is not perfectly selective: it can also raise cortisol and prolactin, and it reliably increases appetite [2]. Newer secretagogues were designed specifically to avoid those off-target effects.
Read this before the hype: GHRP-2 is not FDA-approved and is commonly sold “for research use only.” This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. GHRP-2 is prohibited in sport by WADA, and its legal status varies by country and is changing.
| Claim area | Mechanism | Evidence maturity | Status |
|---|---|---|---|
| GH release | Ghrelin-receptor (GHS-R1a) agonism | Human (short-term) | Diagnostic use, Japan only [4] |
| Appetite increase | Ghrelin mimicry | Human pilot [2] | Not FDA-approved |
| Tissue protection | GHS-R1a / CD36 signaling | Animal + in-vitro [3] | Preclinical only |
| Muscle / anti-aging | Assumed via GH | No controlled human trials | Unproven marketing claim |
Key takeaways
- GHRP-2 (pralmorelin) is a ghrelin-receptor agonist that triggers a large, short-lived growth hormone pulse in humans [1].
- Its only regulatory approval is as a growth hormone deficiency diagnostic agent in Japan, not as a therapy [4].
- GHRP-2 increased food intake by roughly 36 percent in a small human crossover study, reflecting its ghrelin-like appetite effect [2].
- Cytoprotective effects exist only in animal and in-vitro models and have not been confirmed in people [3].
- GHRP-2 is banned in sport by WADA and is sold research-use-only, so muscle and anti-aging claims remain unproven.
Frequently asked questions
What are the main GHRP-2 benefits shown in research?
The clearest documented effects are a strong growth hormone pulse and increased appetite in human studies. Broader benefits like muscle growth or anti-aging are marketed but not supported by controlled human trials.
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin is the formal drug name for GHRP-2, marketed in Japan as GHRP Kaken 100 for diagnosing growth hormone deficiency.
How does GHRP-2 raise growth hormone?
It binds the ghrelin receptor (GHS-R1a) on the pituitary and hypothalamus, which triggers release of stored growth hormone. This is a different pathway from GHRH.
Is GHRP-2 approved by the FDA?
No. GHRP-2 has no FDA approval and is commonly sold for research use only. Its only regulatory approval anywhere is as a diagnostic agent in Japan.
Does GHRP-2 have side effects?
Human studies report increased hunger, and GHRP-2 can also raise cortisol and prolactin because it is not fully selective. Long-term safety in healthy adults has not been established.
Is GHRP-2 legal to use?
It is banned in sport by WADA and is not an approved therapy in the US or Europe. Legal status differs by country and is changing, so verify current rules before relying on any claim.
GHRP-2 sits within the growth hormone secretagogue family alongside compounds such as ipamorelin, hexarelin, and GHRP-6, all ghrelin-receptor agonists that provoke pituitary growth hormone release, while GHRH analogs like CJC-1295 act through a separate receptor and are often studied in combination; because pralmorelin also mimics ghrelin it raises appetite and can lift cortisol and prolactin, which is why Compound Universe Genome tracks each of these peptides against the primary endocrinology literature rather than vendor claims.
The realistic read on GHRP-2 benefits is that this peptide reliably spikes growth hormone and appetite in short human studies and serves as a real diagnostic tool in Japan, but the muscle, fat-loss, and anti-aging promises attached to it have no controlled human evidence and it remains a WADA-banned, research-use-only compound. Anyone weighing GHRP-2 benefits should read it as an active research subject, not a validated therapy.
Compare next: GHRP-2 vs ipamorelin | ipamorelin research summary | peptides studied for recovery
References
- Gondo RG, et al. Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor. J Clin Endocrinol Metab. 2001;86(7):3279-3283. PMID 11443201.
- Laferrere B, Abraham C, Russell CD, Bowers CY. Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PMID 15699539 / PMC2824650.
- Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. PMC5392015.
- Pralmorelin (GHRP Kaken 100), Kaken Pharmaceutical, approved in Japan (2004) as a diagnostic agent for growth hormone deficiency; WADA-prohibited; no FDA approval. Source: Pralmorelin, Wikipedia (regulatory summary), accessed July 2026.